Cargando…

PM380. Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia

Detalles Bibliográficos
Autor principal:	Chen, Yi-hsing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616316/ http://dx.doi.org/10.1093/ijnp/pyw041.380

Ejemplares similares

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

PM481. Tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate in patients hospitalized for an exacerbation of schizophrenia
por: Schreiner, Andreas, et al.
Publicado: (2016)

PM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
por: Brown, Brianne, et al.
Publicado: (2016)

PM383. Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER
por: Chung, Young-Chul
Publicado: (2016)

Successful treatment using combined electroconvulsive therapy and oral paliperidone for clozapine-resistant schizophrenia: A case report
por: Varlam, C. I., et al.
Publicado: (2023)

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
por: Savitz, Adam, et al.
Publicado: (2016)

PM511. Determinants of Caregiver Burden in Family Carers of Asian Patients with Schizophrenia treated with Paliperidone Palmitate 3-monthly injectable
por: Srihari, Gopal,, et al.
Publicado: (2016)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double–blind, multicentric trial
por: Shah, Sandip, et al.
Publicado: (2011)

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
por: Birnbaum, Michael, et al.
Publicado: (2008)

Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice
por: Peuskens, Joseph, et al.
Publicado: (2014)

PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
por: Savitz, A, et al.
Publicado: (2016)

PM378. A reduced risk of severe hepatic outcome with paliperidone exposure in schizophrenia patients with viral hepatitis: a population-based retrospective cohort study
por: Chang, Chun-Hung, et al.
Publicado: (2016)

PM480. Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - A Retrospective Observational Study
por: Schreiner, Andreas, et al.
Publicado: (2016)

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
por: Mathews, Maju, et al.
Publicado: (2016)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

PM416. Efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic: off-label use in first-episode adolescent schizophrenic patients
por: Petrić, Daniela, et al.
Publicado: (2016)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach
por: Mauri, Mauro, et al.
Publicado: (2015)

PM479. Clinical and Functional Response to Paliperidone Palmitate in Early Schizophrenia – A Retrospective Observational Study in Newly Diagnosed Patients Treated Over a 12-Month Period
por: Schreiner, Andreas, et al.
Publicado: (2016)

Drug utilization of paliperidone in adolescent schizophrenia patients: A retrospective cohort study in China
por: Dong, S., et al.
Publicado: (2021)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
por: Bellino, Silvio, et al.
Publicado: (2011)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia
por: Salzman, Phyllis, et al.
Publicado: (2016)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
por: Najarian, D., et al.
Publicado: (2023)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

380. The first two years of the European VACCELERATE volunteer registry
por: Salmanton-Garcia, Jon, et al.
Publicado: (2023)

Paliperidone ER: a review of the clinical trial data
por: Janicak, Philip G, et al.
Publicado: (2007)

PM414. The impact of long acting paliperidone palmitate on clinical outcomes and hospital stay in routine clinical practice: a UK service evaluation
por: Pappa, Sofia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mthcqakjo9a6i34a3qm1qiuail